*Please make sure that you read carefully the Legal Statement and About the Company’ s Snapshot before reading the PDF and be aware that the information contained in the webpage shall always prevail over the PDF under any circumstances.

Asymchem Laboratories (Tianjin) Co., Ltd.

Code: 002821 ISIN: CNE100002BZ6

Founded	10/08/1998	Email	securities@asymchem.com.cn
Listing	11/18/2016	Telephone	(+86)22-66389560
Website	www.asymchem.com.cn	Fax	(+86)22-66252777
Domicile	No.6, Dongting 3rd Street, Economic and Technogical Development Zone, Tianjin	Office	No. 71, 7th Avenue, Economic and Technogical Development Zone, Tianjin

Business Summary (Updated: 09/01/2025)

Asymchem is a leading, technology driven CDMO providing comprehensive solutions and services throughout the drug development and manufacturing process. Our Company’ s industry experience covers more than two decades in small molecule drug development and manufacturing and has become an integral part of the global value chain for innovative drugs. With extensive know-how and advanced technologies, the Company has collaborated with diversified largest global pharmaceutical companies and has become the leading small molecule CDMO in China. Drawing on our extensive industry knowledge, well-established R&D platforms, manufacturing capabilities, and stellar reputation with customers, we have enhanced our CDMO offerings to encompass cutting-edge drug modalities. These include peptides, oligonucleotides, monoclonal antibodies (“mAbs”), antibody-drug conjugates (“ADCs”), and messenger RNA (“mRNA”). Furthermore, we have expanded our service portfolio to encompass chemical macromolecule CDMO solutions, drug product solutions, biosynthesis solutions, and clinical CRO solutions, collectively referred to as our Emerging Services. Our vision is to become a reliable partner for the global pharmaceutical industry, providing superior one-stop CDMO services and solutions throughout the full lifecycle of drugs from their development to commercialization.

Highlights (Updated: 09/01/2025)

Leveraging Asymchem’ s management team’ s global vision, intensive strategy, and local expertise, Asymchem is well positioned to capture the growing trend of global CDMO outsourcing to China, with its technological leadership and extensive know-how, established long-term relationships with global leading biopharma/biotechnology companies, as well as service capability expansion into new modalities and service types.

We have continued to develop as a technology driven CDMO providing comprehensive solutions with strong revenue growth performance of the flagship services through small molecule and emerging business services. Asymchem has amassed over decades of experience and solidified its position in the small molecule business. Our collaborations with international multinational pharmaceutical companies have grown stronger.

We strive to further advance our market leadership in the small molecule CDMO market through the established reputation, advanced R&D platforms, robust manufacturing capabilities and high-quality customer services to diversified multinational pharmaceutical companies and leading biotechnology companies across different jurisdictions. Derived from six business lines of the emerging services segment, we spotted on peptide and oligonucleotide in chemical macromolecules, captured the blooming of biological macromolecules through integration service of ADC, various conjugated drugs, and payload linkers, and promoted export continuous flow technology and synthetic biology Technology. The two flagship technologies have evolved from individual components into full-fledged technological platforms. We can now offer external technology output, enabling partners from diverse fields to leverage our cutting-edge technological achievements to address their own pain points, leading to notable enhancements in efficiency and safety while significantly reducing costs. By leveraging the deep industry insights, we will continue to push forward emerging business, which we believe will drive the diauxic growth curve of the Company through the number of blockbuster drugs and several drug candidates of our other innovative projects which hold great promise to become blockbuster drugs in the future.

We have enriched the first-class operational and quality management capabilities meeting the stringent requirements from clients and global industry standards and have built a decent industry reputation. Our extensive technical know-how in process development makes us a preferred choice for large customers. We can expediently solve a variety of complex process challenges in the scale-up production of innovative drugs, accelerating clinical development process and providing high-quality enhancement of yield and stable production during the commercial stage. Based on years of largescale manufacturing experience, we have established a comprehensive, rigorous Current Good Manufacture Practices (“cGMP”) quality system and a first-class environmental, health, and safety (“EHS”) and quality assurance (“QA”) system. In the past, we have an outstanding track record of ESH and EA system compliance and further extensive improvement and development on the rapid upgrading of supplier requirements from several clients i.e. multiple pharmaceutical companies through their individual ESG standards.

We have maintained a stable, visionary, experienced senior executive management team who have long-term industry and operation experience with a sophisticated corporate governance sense, supported by talented and dedicated employees. Our Company is led by the founder, Chairperson, and CEO Dr. Hao Hong and a group of senior executives with an average of more than 20 years of profound experience in their respective fields. The management team is also very stable with multiple members joining during the early days of the Company and several others who have been at the Company for over 10 years. Combined with the diversified talent pool and employees with a global vision, advanced technical knowledge, sturdy execution capabilities, and a strong sense of ownership, it is likely to continue driving the Company’ s growth.

Investment Risks (Updated: 09/01/2025)

1. Risk that innovative drugs are delisted or recalled largely: If drugs’ quality cannot be controlled or any problems on quality control is appeared, drugs will be recalled probably and customized demands of cGMP advanced intermediates and API will decrease.
2. Innovative drugs’ period is replaced and the sales on market are lower than the expectation.
3. Operational risks on projects in clinical stage: Pharmaceutical companies will be forced to cut demands for

Trading Information

CSRC Sector	Manufacturing
CSRC Subsector	Pharmaceutical Manufacturing
Market	Main Board of Shenzhen Stock Exchange

Directors & Executives

Chairman of the Board:	Hao Hong
General Manager:	-
Chief Financial Officer:	Zhang Da
Board Secretary:	Xu Xiangke
Board Members:	Hao Hong,Yang Rui,Zhang Da,Hong Liang,Zhang Ting,Ye Song,Sun Xuejiao,Hou Xinyi

Top 5 Shareholders (Ended: 09/30/2025)

Name	Shares Held(M.)	%Own
Asymchen Laboratories, Incorporated	115.13	31.93
HKSCC Nominees Limited	27.55	7.64
Industrial and Commercial Bank of China Limited - Zhong Ou Medical and Health Mixed Fund	16.32	4.53
Hao Hong	14.27	3.96
Hong Kong Securities Clearing Company Limited	13.29	3.68

Operating Revenue (Unit: Million)

	1Q	Semi-annual	3Q	Annual
2025	1,541	3,188	4,630	-
2024	1,400	2,697	4,140	5,805
2023	2,249	4,622	6,383	7,825
2022	2,062	5,041	7,812	10,255
2021	777	1,760	2,923	4,639
2020	475	1,266	2,083	3,150
2019	476	1,093	1,742	2,460
2018	364	758	1,205	1,835
2017	290	551	896	1,423
2016	-	470	786	1,103

outsourcing R&D of innovative drugs large by global economic downward pressure and rising finical crisis which will have negative impacts on projects in clinical stages.

4. It is risky to fail in continuous audit by international drug regulatory agency.

5. Uncertain risk on continuous and high investment on R&D: It will have negative impacts on future profits by uncertain R&D failure and lower estimated returns.

6. Risk on core technical personnel loss.

7. Risk on operation in overseas market.

8. Risk on environment and safe production.

9. Risk on international trade frictions.

Dividend Data

Cash Div./Share( )	Bonus Issue/Share	Stock Div./Share	Date Decl.	Ex-Div.Date	Record Date	Cash Pay Day	Share Pay Day
1.100	-	-	06/19/2025	06/26/2025	06/25/2025	06/26/2025	-
1.800	-	-	06/24/2024	06/28/2024	06/27/2024	06/28/2024	-
1.800	-	-	06/20/2023	06/28/2023	06/27/2023	06/28/2023	-
0.800	0.400	-	07/14/2022	07/21/2022	07/20/2022	07/21/2022	07/21/2022
0.600	-	-	07/07/2021	07/13/2021	07/12/2021	07/13/2021	-
0.500	-	-	06/17/2020	06/24/2020	06/23/2020	06/24/2020	-
0.400	-	-	05/31/2019	06/10/2019	06/06/2019	06/10/2019	-
0.350	-	-	05/19/2018	05/25/2018	05/24/2018	05/25/2018	-
0.500	1.000	-	06/08/2017	06/14/2017	06/13/2017	06/14/2017	06/14/2017

Per Share Data (FYE: 12/31)

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Earnings( )	2.6900	6.2600	9.0200	4.4000	3.1000	2.4200	1.8800	1.5100	2.7500	-
Prices: High( )	116.22	174.55	422.00	532.49	301.50	145.85	93.87	153.34	146.80	-
Prices: Low( )	59.55	112.16	124.72	227.50	124.16	63.50	49.12	52.50	36.64	-

Financials

Income Statement (Unit: Million ; FYE: 12/31)

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Operating Revenue	5,805	7,825	10,255	4,639	3,150	2,460	1,835	1,423	1,103	831
Operating Costs	3,346	3,822	5,398	2,582	1,683	1,341	982	687	534	430
Operating Income	1,079	2,571	3,731	1,192	817	624	461	420	315	200
Pretax Income	1,072	2,557	3,725	1,193	814	624	461	422	325	200
Income Tax	137	306	430	124	92	70	54	62	50	30
Net Income	936	2,251	3,295	1,069	722	554	406	360	276	170

Balance Sheet (Unit: Million ; FYE: 12/31)

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Assets										
Monetary Capital	5,789	7,110	5,290	6,234	2,125	435	630	839	1,084	265
Current Assets-Total	11,050	12,352	11,860	10,310	4,030	1,639	1,694	1,615	1,645	666
Non-current Assets-Total	8,238	7,415	6,379	4,846	3,128	2,120	1,491	1,022	800	605
Total Assets	19,289	19,767	18,239	15,156	7,158	3,759	3,185	2,637	2,445	1,272
Liabilities										
Current Liabilities-Total	1,709	1,801	2,177	2,205	925	504	540	374	504	237
Long-term Debt	-	-	-	-	-	-	-	-	-	-
Non-current Liabilities-Total	717	456	367	341	238	209	135	108	108	98
Total Liabilities	2,426	2,257	2,544	2,546	1,163	713	675	482	612	334
Stockholder's Equity										
Share Capital	368	369	370	263	242	231	231	230	113	90
Retained Profits	8,078	7,760	6,155	3,170	2,287	1,698	1,252	909	632	423
Total Owners' Equity	16,863	17,510	15,695	12,610	5,995	3,046	2,511	2,155	1,833	937

Cash Flow Statment (Unit: Million ; FYE: 12/31)

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Net Cash Flows-Operating	1,254	3,550	3,287	113	569	601	415	196	278	257
Net Cash Flows-Investing	-1,184	-2,691	-4,671	-2,205	-1,102	-700	-584	-300	-200	-141
Net Cash Flows-Financing	-1,928	-542	-743	6,211	2,268	-102	-43	-65	682	-13